Author

Shan Feng

University of Notre Dame

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:host-pathogen & immune response· 1 Approach:microscopy & imaging analysis· 1

Frequent Co-Authors

Ariana ArceiD· 1 shared Bo-Xin Zhang· 1 shared Guoqiang LiuiD· 1 shared Haibing ZhangiD· 1 shared Huan-Feng Ye· 1 shared Huipeng JiaoiD· 1 shared Jia Huang· 1 shared Jie Zhang· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Ariana ArceORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Oxidation-Driven mtDNA B-Z Transition Activates ZBP1 to Mediate Acetaminophen Hepatotoxicity

Zhang-Hua Yang, Bo-Xin Zhang, Huan-Feng Ye, Liang Shi, Rui Gong, Zhiyu Cai, Qiang Chen, Lei Wu, Jia Huang, Le Zhang, Huipeng Jiao, Pinglong Xu, Qinjie Weng, Jie Zhang, Jinheng Pan, , Wei Mo

This study identifies oxidative mtDNA B-Z transitions activating ZBP1 as a key mechanism in APAP-induced liver failure and shows TH107854 can reverse this process.

Vita · Jan 1, 2026Peer-reviewedCell Biology

CDH3 as a Novel Therapeutic Target in Basal-like Double-Negative Prostate Cancer

Guoqiang Liu, Shiyu Wang, Loan Duong, Ziyu Zeng, Jing Hui Yang, Yun Zhao, Sharif Rahmy, Shan Feng, Ariana Arce, Lin Jia, Jun Wan, Liang Cheng C, Xuemin Lu, Xin Lü

This study identifies CDH3 as a key driver of basal-like prostate cancer and shows that CDH3-targeted therapies like ADCs and CAR T cells are effective in preclinical models.

bioRxiv · Nov 18, 2025 · PreprintCancer Biology